The table below shows Allogene Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$0.00
$22.00K
$95.00K
$156.00K
$114.09M
$0.00
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$150.15M
$192.30M
$242.91M
$256.39M
$220.18M
$192.99M
SG&A
$56.78M
ALLO annual revenue (10-K history)
Allogene Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $22.00K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.